SCHEMBL12953070

SCHEMBL12953070

CC(C)(C)c1ccc(Oc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2O)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 3/20 0.42
▸ SERPINE1 P05121 1/20 0.41
▸ ABL1 P00519 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ TPX2 Q9ULW0 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ XDH P47989 1/20 0.38
▸ AKR1C2 P52895 1/20 0.38
▸ AKR1C1 Q04828 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ PPARD Q03181 2/20 0.38
▸ SCN5A Q14524 2/20 0.37
▸ PTPN2 P17706 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13580929 0.92 TRPV1 (0.45) TRPV1SERPINE1ABL1AURKATPX2
SCHEMBL13581087 0.87 IDO1 (0.39) TRPV1SERPINE1ABL1AURKATPX2
SCHEMBL13580959 0.84 AURKA (0.47) ABL1AURKATPX2AKR1C2AKR1C1
SCHEMBL12952954 0.83 PPARD (0.43) TRPV1SERPINE1ABL1AURKATPX2
SCHEMBL13580799 0.81 EPHX2 (0.46) TRPV1SERPINE1EPHX2NR1H4XDH
SCHEMBL13580812 0.81 TRPV1 (0.45) TRPV1SERPINE1AURKATPX2ALDH1A1
SCHEMBL13580939 0.81 TRPV1 (0.47) TRPV1ALDH1A1HPGDEPHX2NR1H4
SCHEMBL12732779 0.80 NPSR1 (0.43) TRPV1ALDH1A1HPGDALOX15HSD17B10
SCHEMBL12952661 0.79 TTR (0.49) SERPINE1ABL1AURKATPX2HSD17B10
SCHEMBL6015487 0.79 ALDH1A1 (0.61) TRPV1ALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
EP-2272817-A1 PAI-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2011-01-12 — — EP disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
WO-2009125606-A1 PAI-1 INHIBITOR 株式会社医薬分子設計研究所 (JP) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 TRPV1 4862/4885SERPINE1 2/4885ABL1 3997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback